J. Dunn

发表

Human KIR+CD8+ T cells target pathogenic T cells in Celiac disease and are active in autoimmune diseases and COVID-19

Mark M. Davis, Ansuman T. Satpathy, L. Steinmetz, 2021, bioRxiv.

Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL.

G. Pardo, J. Guthridge, Y. Mao-Draayer, 2022, Multiple sclerosis and related disorders.

An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis: Advocacy, Dissemination, and Implementation Strategies.

D. Reich, F. Barkhof, F. Paul, 2020, International journal of MS care.

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis

L. Weiner, A. Traboulsee, D. Pelletier, 2020, Journal of Neuroinflammation.

IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity

L. Steinman, G. Pardo, J. Guthridge, 2015, The Journal of Immunology.

Efficacy in Neuroautoimmunity Treatment Requires B Cells for β IFN

L. Steinman, G. Pardo, J. Guthridge, 2015 .

KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19

Mark M. Davis, Ansuman T. Satpathy, L. Steinmetz, 2022, Science.

Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM

Mark S. Anderson, J. Derisi, B. Ueberheide, 2022, Nature.

Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management

S. Deresinski, David J. Epstein, J. Dunn, 2018, Open forum infectious diseases.

Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis

J. Dunn, 2010, Expert review of pharmacoeconomics & outcomes research.

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

D. Arnold, A. Bar-Or, M. Freedman, 2008, Multiple sclerosis.

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis

L. Weiner, A. Traboulsee, D. Pelletier, 2020, Journal of Neuroinflammation.

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis

A. Blight, J. Dunn, 2011, Current medical research and opinion.

Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein

C. Polman, L. Steinman, M. Han, 2012, Multiple sclerosis.

Disease-modifying therapies for nonrelapsing multiple sclerosis: Absence of evidence does not constitute evidence of absence.

J. Dunn, 2013, Neurology. Clinical practice.

Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM

Mark S. Anderson, J. Derisi, B. Ueberheide, 2022, Nature.

IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity

L. Steinman, G. Pardo, J. Guthridge, 2015, The Journal of Immunology.